 |
PDBsum entry 1dvq
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hormone/growth factor
|
PDB id
|
|
|
|
1dvq
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Rational design of potent human transthyretin amyloid disease inhibitors.
|
 |
|
Authors
|
 |
T.Klabunde,
H.M.Petrassi,
V.B.Oza,
P.Raman,
J.W.Kelly,
J.C.Sacchettini.
|
 |
|
Ref.
|
 |
Nat Struct Biol, 2000,
7,
312-321.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The human amyloid disorders, familial amyloid polyneuropathy, familial amyloid
cardiomyopathy and senile systemic amyloidosis, are caused by insoluble
transthyretin (TTR) fibrils, which deposit in the peripheral nerves and heart
tissue. Several nonsteroidal anti-inflammatory drugs and structurally similar
compounds have been found to strongly inhibit the formation of TTR amyloid
fibrils in vitro. These include flufenamic acid, diclofenac, flurbiprofen, and
resveratrol. Crystal structures of the protein-drug complexes have been
determined to allow detailed analyses of the protein-drug interactions that
stabilize the native tetrameric conformation of TTR and inhibit the formation of
amyloidogenic TTR. Using a structure-based drug design approach
ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl)
phenoxazine 4, 6-dicarboxylic acid have been discovered to be very potent and
specific TTR fibril formation inhibitors. This research provides a rationale for
a chemotherapeutic approach for the treatment of TTR-associated amyloid diseases.
|
 |
 |
 |
|
 |
|
 |
Figure 5.
Figure 5. Comparison of binding of flurbiprofen to TTR and
COX-2. a, Hormone binding channel of TTR with bound
flurbiprofen. In each binding conformation flurbiprofen fills
three halogen binding pockets: the phenyl ring binds into the
innermost HBP-3, the fluorine substituent into HBP-2, and the
-methyl
group into HBP-1. b, Binding of the anti-inflammatory
flurbiprofen into the prostaglandin binding channel of COX-2
(PDB 3PGH)28. The binding channel has two entrances, one on the
top and one on the left. The CH[2]COOH group of flurbiprofen is
positioned at one of the entries close to the gate residue Arg
120 and thus allows the formation of a salt bridge. As in the
TTR -FLP complex further protein -ligand interactions are
augmented by hydrophobic interactions between the biphenyl
moiety of the drug and hydrophobic protein residues.
|
 |
Figure 6.
Figure 6. Hormone binding channel of TTR with bound novel
designed amyloid inhibitors. a, o-trifluoromethylphenyl
anthranilic acid (oFLU). b, Dibenzofuran-4,6-dicarboxylic acid
(DDBF), c,
N-m-trifluoromethylphenyl-phenoxazine-4,6-dicarboxylic acid
(PHENOX).
|
 |
|
 |
 |
|
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2000,
7,
312-321)
copyright 2000.
|
 |
|
|
|
|
 |